
US-based Eli Lilly and Regor Therapeutics Group have entered into a development collaboration and licensing agreement to discover, develop and commercialize new therapies within metabolic diseases like diabetes and obesity.
As part of the deal, Eli Lilly will have the option to license Regor's technology and discoveries. Eli Lilly will then be responsible for the clinical development, production and commercialization on a global scale, excluding China, Macau, Hong Kong and Taiwan, where Regor will retain the rights.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app